Jim S. Adler & Associates’ defective drug lawyers in Houston and throughout the state handle cases involving COX 2 inhibitors such as Bextra. 

Bextra research conducted under the leadership of Dr. Garret FitzGerald, a cardiologist and pharmacologist at the University of Pennsylvania, indicates that individuals taking Bextra have a 219% greater chance of complications and risks involving: heart attack, stroke, sudden death, and/or Stevens Johnson Syndrome. Dr. FitzGerald, one of the world's leading COX-2 inhibitor experts, presented his research results to a meeting of the American Cardiology Association. Dr. Garret Fitzgerald, called Bextra, "A time bomb waiting to go off," and noted that the apparent dangers of Bextra exceed those associated with Vioxx.

This is alarming news considering COX-2 drugs is a class of medicine that includes Vioxx, Bextra, and Celebrex, which is also made by Pfizer. Vioxx had sales of $2.5 billion last year, while Celebrex had sales of $1.8 billion and Bextra $687 million. Analysts project worldwide sales of Celebrex this year to be $3.4 billion and $1.3 billion for Bextra.